Drugs /

e7090

Back to Drugs List

Overview

NCI Definition [1]:
An inhibitor of the fibroblast growth factor (FGF)/fibroblast growth factor receptor (FGFR) pathway, with potential antineoplastic activity. Upon administration, the FGF/FGFR pathway inhibitor E7090 selectively interferes with the binding of FGF to FGFR through an as of yet not fully elucidated mechanism. This inhibits FGFR-mediated signaling and leads to both cell proliferation inhibition and cell death in FGFR-overexpressing tumor cells. FGFR is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation, and survival; its expression is upregulated in many tumor cell types.

Clinical Trials

View Clinical Trials for e7090

E7090 has been investigated in 4 clinical trials, of which 4 are open and 0 are closed. Of the trials investigating e7090, 2 are phase 1 (2 open) and 2 are phase 2 (2 open).

FGFR2 Fusion, FGFR1 Amplification, and FGFR1 Fusion are the most frequent biomarker inclusion criteria for e7090 clinical trials.

Malignant solid tumor, breast carcinoma, and intrahepatic cholangiocarcinoma are the most common diseases being investigated in e7090 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating E7090
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating e7090 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
fgf/fgfr pathway inhibitor e7090, fgf/fgfr pathway inhibitor e7090
Drug Target(s) [2]:
FGFR1, FGFR2, FGFR3
NCIT ID [1]:
C118672

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.